Skip to main content

Caribou Biosciences, Inc. (CRBU)

NASDAQ: CRBU · IEX Real-Time Price · USD
24.15 0.63 (2.68%)
Sep 21, 2021 1:49 PM EDT - Market open
Market Cap1.34B
Revenue (ttm)12.25M
Net Income (ttm)-37.67M
Shares Out55.53M
EPS (ttm)-0.68
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume712,949
Open23.90
Previous Close23.52
Day's Range23.05 - 25.60
52-Week Range15.00 - 32.65
Betan/a
Analystsn/a
Price Target30.67 (+27.0%)
Est. Earnings DateNov 11, 2021

About CRBU

Caribou Biosciences is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying our novel CRISPR platform, chRDNA toward the development of next-generation, genome-edited cell therapies. We believe that our technology has broad potential to generate gene and cell therapies in oncology and in therapeutic areas beyond oncology, including immune cell therapies, cell therapies derived from genome-edited iPSCs, and in vivo genome-editing therapies. We are initially focused on ad...

IndustryBiotechnology
IPO DateJul 23, 2021
CEORachel E. Haurwitz, Ph.D.
Employees66
Stock ExchangeNASDAQ
Ticker SymbolCRBU
Full Company Profile

Financial Performance

Financial Statements

News

Caribou Biosciences Provides Business Update and Reports Second Quarter 2021 Financial Results

Completed upsized initial public offering of common stock, raising $349.6 million in gross proceeds including full exercise of underwriters' option to purchase additional shares

2 weeks ago - GlobeNewsWire

Caribou Biosciences Announces Publication of Data Demonstrating High Specificity Genome Editing with its Proprietary ...

Data published in Molecular Cell provide a mechanistic framework to explain the enhanced specificity and key differentiation of Caribou's proprietary chRDNA technology for therapeutic applications

2 weeks ago - GlobeNewsWire

Caribou Biosciences Appoints Nancy Whiting, Pharm.D., to its Board of Directors

BERKELEY, Calif., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that it has appoin...

3 weeks ago - GlobeNewsWire

Caribou Biosciences Announces Closing of Upsized Initial Public Offering

BERKELEY, Calif.--(BUSINESS WIRE)---- $CRBU--Caribou Biosciences, Inc., (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the closing of its previ...

1 month ago - Business Wire

3 Reasons Caribou Biosciences Could Be the Best Gene-Editing Stock for Your Portfolio

The company has a pedigree and a novel approach that could put it at the top of the CRISPR heap.

1 month ago - The Motley Fool

Caribou Biosciences Announces Pricing of Upsized Initial Public Offering

BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the pricing of its upsized initial public offering...

1 month ago - Business Wire

Caribou Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial Evaluating CB-010, a CRISPR-Edited Al...

BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that the first patient has been dosed in its open-...

2 months ago - Business Wire

Caribou Biosciences Eyes $100M NASDAQ Debut To Propel Off-The-Shelf CAR-T Therapies In Blood Cancer

In a filing with SEC on Thursday, Caribou Biosciences (NASDAQ: CRBU) is penciling in a $100 million initial public offering. The firm expects that its new shares will trade on the NASDAQ under the symbo...

2 months ago - Benzinga

Caribou Biosciences IPO Registration Document (S-1)

Caribou Biosciences, Inc. has filed to go public with an IPO on the NASDAQ.

2 months ago - SEC